Product Description
GTAEXS-617 is a novel CDK7 inhibitor that has been designed by Exscientia in collaboration with GT Apeiron for high potency, selectivity, bioavailability and safety. CDK7 inhibition combines cell cycle disruption with transcription inhibition, making it an attractive target to overcome common resistance pathways in CDK4/6 inhibition. (Sourced from: https://investors.exscientia.ai/press-releases/press-release-details/2022/Exscientia-Presents-Novel-Patient-Stratification-and-Biomarker-Data-for-GTAEXS-617-at-the-34th-EORTC-NCI-AACR-Annual-Symposium/default.aspx)
Mechanisms of Action: CDK7 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Recursion Pharmaceuticals
Company Location: SALT LAKE CITY UT 84101
Company CEO: Christopher Gibson
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Exscientia announced they will present P1 Oncology Solid Tumor Unspecified results in 2H24 for GTAEXS-617
Highest Development Phases
Phase 2: Adenocarcinoma|Breast Cancer|Colorectal Cancer|Head and Neck Cancer|Non-Small-Cell Lung Cancer|Oncology Solid Tumor Unspecified|Ovarian Cancer|Pancreatic Cancer|Small Cell Lung Cancer|Squamous Cell Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| ELUCIDATE | P2 |
Recruiting |
Adenocarcinoma|Ovarian Cancer|Pancreatic Cancer|Breast Cancer|Small Cell Lung Cancer|Squamous Cell Carcinoma|Head and Neck Cancer|Non-Small-Cell Lung Cancer|Colorectal Cancer |
2028-01-01 |
36% |
2023-08-15 |
Primary Endpoints|Treatments |
| GTAEXS617-001 | P2 |
Recruiting |
Oncology Solid Tumor Unspecified |
2027-11-11 |
2025-05-02 |
Treatments |
|
| GTAEXS617 in patients with advanced solid tumours | P2 |
Active, not recruiting |
Oncology Solid Tumor Unspecified |
2027-07-23 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
08/15/2024 |
News Article |
Exscientia Business Update for Second Quarter and First Half 2024 |
|
08/06/2024 |
News Article |
Latest Updates of Viva Biotech's Portfolio Companies |
|
07/18/2024 |
News Article |
Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout |
|
05/21/2024 |
News Article |
Exscientia Business Update for First Quarter 2024 |